Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals.
The epidemiology of Staphylococcus epidermidis in U.S. hospitals remains limited. This study aimed to address the genetic backgrounds of linezolid-susceptible and -resistant S. epidermidis strains (isolated in 2010), including cfr-carrying strains. In addition, the antimicrobial susceptibility profiles and linezolid resistance mechanisms among clonal lineages were assessed. A total of 71 S. epidermidis isolates were selected, and linezolid-resistant strains were screened for cfr and mutations in 23S rRNA, L3, and L4. All isolates were subjected to multilocus sequence typing (MLST), and the results were analyzed by eBURST. Overall, 27 sequence types (STs) were detected, and ST5 (21.1%) and ST2 (16.9%) predominated. The majority (62/71; 87.3%) of STs belonged to clonal complex 2 (CC2), which was mostly comprised of subclusters CC2-II (41/62; 66.1%) and CC2-I (21/62; 33.9%). Other STs were grouped within CC23 or CC32 or were singletons. CC2-I strains were more likely to display a methicillin (95.2% versus 33.3 to 70.7%), a linezolid (47.6% versus 0.0 to 7.3%), or a multidrug (81.0% versus 33.3 to 36.6%) resistance phenotype. Among linezolid-resistant isolates, cfr was noted only within CC2 strains, and it was detected equally in the CC2-I (3/10; 30.0%) and CC2-II (1/3; 33.3%) subclusters. 23S rRNA mutations (G2576 [seven strains] and C2534 [one strain]) were observed only among CC2-I (8/10; 80.0%) isolates. Strains showing a G2576 alteration also had M156 (7/7; 100.0%) and/or H146 (6/7; 85.7%) L3 modifications. This study provides an overview of the S. epidermidis clonal distribution and reports higher resistance rates among CC2-I strains. The results show that cfr may be acquired and expressed by both CC2 main subclusters, while 23S rRNA mutations appeared more often within CC2-I strains. Interestingly, these 23S rRNA mutants also had L3 alterations, which may act synergistically or in a compensatory manner to minimize the fitness cost while providing survival advantages under selective pressure.
JMI Laboratories, North Liberty, Iowa, USA. rodrigo-mendes@jmilabs.com
Rodrigo E
RE
Mendes
Lalitagauri M
LM
Deshpande
Andrew J
AJ
Costello
David J
DJ
Farrell
D000081:Acetamides / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics*; D015373:Bacterial Typing Techniques; D002675:Child, Preschool; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D005260:Female; D006761:Hospitals; D006801:Humans; D007223:Infant; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D005810:Multigene Family; D058885:Multilocus Sequence Typing; D009154:Mutation; D023303:Oxazolidinones / Q000494:pharmacology; D010802:Phylogeny; D012338:RNA, Ribosomal, 23S / Q000235:genetics*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D013212:Staphylococcus epidermidis / Q000145:classification / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D014481:United States / Q000453:epidemiology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D023303:Oxazolidinones; D012338:RNA, Ribosomal, 23S; D000069349:Linezolid